THerapeutic Oncolytic Monitoring AS a tool for effective exposure to 5-FU in patients with locally advanced, resectable gastric or gastro-oesophageal junction cancer treated with perioperative FLOT
- Conditions
- Gastric cancer1001799010017987
- Registration Number
- NL-OMON51680
- Lead Sponsor
- Catharina-ziekenhuis
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 20
1. Pathologically confirmed malignancy for which treatment with 5-FU is
indicated in the FLOT regimen.
2. Age >= 18 years
3. Patient is able and willing to give written informed consent
4. WHO performance status 0-2
5. Patient fulfills the general treatment criteria for treatment with FLOT
including appropriate liver and renal function and other standard applicable
laboratory values
6. Patient is able and willing to undergo extra blood sampling for 5-FU
analysis
1. Patients with known substance abuse, psychotic disorders, and/or other
diseases expected to interfere with study or the patient*s safety.
2. Inability to undergo additional blood sampling.
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.